Member Posts > CRD-38 Demonstrates Mitochondrial Protection in Preclinical Heart Failure Models
A recent study published in JAC: Basic to Translational Science has unveiled compelling evidence for the efficacy of CRD-38, Cardiol Therapeutics' subcutaneous cannabidiol therapy, in preserving mitochondrial function in heart failure models.
The study demonstrated that CRD-38 effectively mitigates oxidative stress and restores calcium homeostasis, critical factors in maintaining cardiomyocyte health. These findings open avenues for cannabidiol's use as a metabolic modulator in heart failure treatment.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx